Transplantation Immunology
Research activity is centred on solid organ transplant rejection, with particular attention to liver, kidney, heart, lung, and intestinal transplantation. The clinical focus includes maintenance of graft function and prevention of immune-mediated rejection in allograft recipients.
- Primary organ transplant rejection prophylaxis
- Allograft maintenance
- Post-transplant immune suppression
The sponsor’s work in this area is closely aligned with long-term care for patients requiring ongoing immunosuppressive therapy after transplantation.
Calcineurin Inhibitor Therapy
Clinical interest extends to tacrolimus treatment and its role in controlling immune activation after transplant. The research landscape includes evaluation of formulations used in routine transplant management and their relevance to stable paediatric and adult patients.
- Tacrolimus exposure
- Formulation switching
- Therapeutic drug monitoring
This area reflects attention to the pharmacology of calcineurin inhibition in maintaining appropriate immunosuppressive coverage.
Paediatric Transplant Care
The sponsor’s clinical research also involves paediatric allograft recipients, with interest in treatment continuity during transitions between transplant medicines. The emphasis is on transplant-related care in children who require sustained immunosuppression.
- Paediatric organ transplantation
- Stable graft recipients
- Long-term transplant follow-up
Attention to this population highlights the clinical importance of age-specific transplant management and ongoing graft protection.
Pharmacokinetics and Blood Exposure Assessment
Research interest includes measurement of tacrolimus blood levels and comparison of drug exposure across transplant formulations. The trial landscape reflects focus on pharmacokinetic behaviour relevant to transplant medicine and dose continuity in stable recipients.
- Blood concentration assessment
- Drug exposure comparison
- Medication conversion in transplantation
This domain supports clinical understanding of how transplant medicines perform in routine use after conversion between formulations.
